Practice-changing research to be presented at the 2018 ASTRO Annual Meeting

By Lisa A. Kachnic, MD, FASTRO, Chair, Annual Meeting Scientific Committee

A strong selection of late-breaking abstracts was submitted for this year’s ASTRO Annual Meeting. A total of 61 abstracts were received within the late-breaking abstracts window between July 19 and August 1, and 10 of them have been selected for oral presentation.

An important, practice-changing study, NRG-RTOG 1016: A Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx, has been added to the Plenary Session. An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall and progression-free survival compared to the current standard treatment with radiation and cisplatin. Full study details will be presented on Monday, October 22 in San Antonio. A second late-breaking abstract has also been added to the Plenary Session, Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial.

Three late-breaking abstracts have been chosen for the Clinical Trials Session. These include:

  • A Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-year Report from NRG/RTOG 9804.
  • FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-year Results.
  • Local Consolidative Therapy Improves Overall Survival Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung cancer: Final Results of a Multicenter, Randomized Controlled Phase II Trial.


The Late-breaking Abstracts Special Session will feature five more late-breaking abstracts:

  • Preservation of Neurocognitive Function with Conformal Avoidance of the Hippocampus During Whole-brain Radiotherapy for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001.
  • Overall survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC.
  • Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPF-associated Oropharyngeal Cancer.
  • An International Randomized Phase III Trial Evaluating Efficacy and Safety in First-in-Class NBTXR3 Hafnium Oxide Nanoparticles Activated by Preoperative Radiotherapy in Locally-advanced Soft Tissue Sarcoma.
  • Preoperative Chemoradiotherapy Potentially Improves Outcome for (Borderline) Resectable Pancreatic Cancer: Preliminary Results of the Dutch Randomized Phase III Preopanc Trial.

Abstracts submitted as late-breaking abstracts must meet specific criteria. Research is limited to highly significant and timely findings in clinical oncology, radiobiology or medical physics that were not available prior to the February 14 abstract submission deadline. Only abstracts deemed to be of high scientific priority are considered for presentation in the Plenary, Clinical Trials or late-breaking abstract sessions, and so standards for accepting late-breaking abstracts for presentation are much higher than those for abstracts accepted for the general scientific sessions.

A special panel of peer reviewers are responsible for selecting abstracts to be presented. All abstracts are scored, and then the Annual Meeting Steering Committee, comprised of the Chair and Vice-chair of the Annual Meeting Scientific and Education Committees, along with the current ASTRO President, President-elect, Education Council Representative, Best of ASTRO Chair and two statisticians discuss which abstracts fit best in these high-level sessions.

View all the scientific and education sessions to be presented at the 60th ASTRO Annual Meeting, taking place October 21-24, 2018, at the Henry B. Gonzalez Convention Center in San Antonio on the Conference Planner. Register for the meeting by September 13 for advance rates.

Posted: August 22, 2018 | with 0 comments

Blog post currently doesn't have any comments.
 Security code

We have recently updated our privacy policy and terms of use.
By using this site, you agree to ASTRO’s Privacy Policy and Terms of Use.
We use cookies to provide, secure and improve our services to you. To learn more, click here.